KCM
CRL icon

Kennedy Capital Management’s Charles River Laboratories CRL Stock Holding History

Kennedy Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.91M Buy
43,719
+85
+0.2% +$15.1K 0.18% 194
2026
Q1 		$7.53M Sell
43,634
-2,019
-4% -$374K 0.16% 219
2025
Q4 		$9.11M Buy
45,653
+1,745
+4% +$317K 0.19% 180
2025
Q3 		$6.87M Sell
43,908
-9,437
-18% -$1.5M 0.15% 236
2025
Q2 		$8.09M Sell
53,345
-30,019
-36% -$4M 0.19% 188
2025
Q1 		$12.5M Buy
83,364
+20,213
+32% +$3.39M 0.3% 103
2024
Q4 		$11.7M Sell
63,151
-17,256
-21% -$3.32M 0.26% 109
2024
Q3 		$15.8M Sell
80,407
-27,075
-25% -$5.63M 0.35% 65
2024
Q2 		$22.2M Sell
107,482
-850
-0.8% -$193K 0.47% 33
2024
Q1 		$29.4M Buy
108,332
+9,466
+10% +$2.26M 0.6% 10
2023
Q4 		$23.4M Buy
98,866
+5,474
+6% +$1.08M 0.51% 29
2023
Q3 		$18.3M Buy
93,392
+997
+1% +$205K 0.45% 39
2023
Q2 		$19.4M Buy
92,395
+33,539
+57% +$6.67M 0.45% 37
2023
Q1 		$11.9M Buy
58,856
+8,726
+17% +$1.98M 0.35% 75
2022
Q4 		$10.9M Buy
50,130
+6,019
+14% +$1.31M 0.31% 94
2022
Q3 		$8.68M Buy
44,111
+5,603
+15% +$1.21M 0.26% 119
2022
Q2 		$8.24M Buy
38,508
+23,019
+149% +$5.62M 0.23% 143
2022
Q1 		$4.4M Buy
15,489
+989
+7% +$305K 0.1% 332
2021
Q4 		$5.46M Sell
14,500
-599
-4% -$233K 0.12% 327
2021
Q3 		$6.23M Sell
15,099
-946
-6% -$393K 0.14% 287
2021
Q2 		$5.93M Sell
16,045
-12,571
-44% -$4.2M 0.13% 316
2021
Q1 		$8.29M Sell
28,616
-4,091
-13% -$1.14M 0.17% 223
2020
Q4 		$8.17M Sell
32,707
-52
-0.2% -$12.4K 0.18% 194
2020
Q3 		$7.42M Sell
32,759
-2,814
-8% -$584K 0.21% 157
2020
Q2 		$6.2M Buy
35,573
+277
+0.8% +$44.2K 0.18% 194
2020
Q1 		$4.46M Buy
35,296
+17,639
+100% +$2.65M 0.16% 220
2019
Q4 		$2.7M Buy
17,657
+2,338
+15% +$324K 0.07% 495
2019
Q3 		$2.03M Sell
15,319
-945
-6% -$127K 0.05% 525
2019
Q2 		$2.31M Buy
16,264
+661
+4% +$89.7K 0.05% 515
2019
Q1 		$2.27M Sell
15,603
-27,581
-64% -$3.62M 0.05% 521
2018
Q4 		$4.89M Sell
43,184
-40,470
-48% -$5.07M 0.12% 316
2018
Q3 		$11.3M Buy
83,654
+2,137
+3% +$264K 0.21% 137
2018
Q2 		$9.15M Buy
81,517
+3,718
+5% +$402K 0.17% 195
2018
Q1 		$8.3M Sell
77,799
-1,273
-2% -$137K 0.16% 198
2017
Q4 		$8.65M Buy
79,072
+2,157
+3% +$235K 0.16% 203
2017
Q3 		$8.31M Buy
76,915
+5,653
+8% +$581K 0.15% 215
2017
Q2 		$7.21M Buy
71,262
+2,627
+4% +$242K 0.14% 252
2017
Q1 		$6.17M Sell
68,635
-23
-0% -$1.95K 0.11% 332
2016
Q4 		$5.23M Buy
68,658
+45,673
+199% +$3.47M 0.09% 402
2016
Q3 		$1.92M Buy
22,985
+2,823
+14% +$237K 0.04% 577
2016
Q2 		$1.66M Buy
+20,162
New +$1.66M 0.03% 600

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Kennedy Capital Management's CRL Position: Q2 2026 in Review

Kennedy Capital Management increased its Charles River Laboratories (CRL) stake by 0.19% in Q2 2026, buying an estimated $15.1K and bringing the position to 43,719 shares worth $9.91M. The position accounts for 0.18% of the portfolio, ranked #194.

Kennedy Capital Management first reported a position in CRL in Q2 2016 and has held it in 41 quarters since. The position peaked at $29.4M in Q1 2024. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Kennedy Capital Management held 43,719 shares of Charles River Laboratories worth $9.91M as of Q2 2026.
  • Kennedy Capital Management bought 85 Charles River Laboratories shares in Q2 2026, an estimated $15.1K.
  • Charles River Laboratories made up 0.18% of Kennedy Capital Management's portfolio in Q2 2026, its #194 holding.
  • Kennedy Capital Management first reported a position in Charles River Laboratories in Q2 2016 and has held it in 41 quarters since.
  • Kennedy Capital Management's Charles River Laboratories position peaked at $29.4M in Q1 2024.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.